Moody National Bank Trust Division lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the 4th quarter, HoldingsChannel reports. The firm owned 210,859 shares of the company’s stock after buying an additional 2,629 shares during the period. Johnson & Johnson makes up about 0.8% of Moody National Bank Trust Division’s holdings, making the stock its 9th biggest position. Moody National Bank Trust Division’s holdings in Johnson & Johnson were worth $27,212,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. Clarus Wealth Advisors lifted its position in shares of Johnson & Johnson by 9.1% during the fourth quarter. Clarus Wealth Advisors now owns 2,994 shares of the company’s stock worth $386,000 after purchasing an additional 250 shares in the last quarter. Bath Savings Trust Co raised its holdings in Johnson & Johnson by 5.8% in the fourth quarter. Bath Savings Trust Co now owns 38,335 shares of the company’s stock valued at $4,948,000 after acquiring an additional 2,091 shares in the last quarter. Silverleafe Capital Partners LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $298,000. Stillwater Investment Management LLC raised its holdings in Johnson & Johnson by 0.7% in the fourth quarter. Stillwater Investment Management LLC now owns 31,117 shares of the company’s stock valued at $4,016,000 after acquiring an additional 216 shares in the last quarter. Finally, Neville Rodie & Shaw Inc. raised its holdings in Johnson & Johnson by 0.8% in the fourth quarter. Neville Rodie & Shaw Inc. now owns 258,914 shares of the company’s stock valued at $33,413,000 after acquiring an additional 2,100 shares in the last quarter. 66.43% of the stock is currently owned by institutional investors and hedge funds.
JNJ has been the topic of several analyst reports. Citigroup reduced their target price on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a report on Wednesday, January 2nd. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 target price on the stock in a report on Wednesday, December 12th. Morgan Stanley set a $140.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Thursday, December 20th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and issued a $152.00 target price (down previously from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $142.81.
Shares of Johnson & Johnson stock opened at $136.91 on Friday. The company has a market capitalization of $367.32 billion, a price-to-earnings ratio of 16.74, a P/E/G ratio of 2.10 and a beta of 0.68. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.02. The company had revenue of $20.39 billion for the quarter, compared to analyst estimates of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The firm’s revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.74 earnings per share. Analysts anticipate that Johnson & Johnson will post 8.57 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th were paid a $0.90 dividend. The ex-dividend date was Monday, February 25th. This represents a $3.60 annualized dividend and a yield of 2.63%. Johnson & Johnson’s dividend payout ratio is currently 44.01%.
Johnson & Johnson declared that its Board of Directors has approved a stock buyback plan on Monday, December 17th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 1.5% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.
WARNING: “Moody National Bank Trust Division Acquires 2,629 Shares of Johnson & Johnson (JNJ)” was published by Highlight Press and is the sole property of of Highlight Press. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://highlightpress.com/2019/03/23/moody-national-bank-trust-division-acquires-2629-shares-of-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.